Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Novartis Pharma AG
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Study of safety of QAW039 in patients (≥ 12 yrs) with asthma inadequately controlled on standard-of-care asthma therapy
Treatment Period 1 (double-blind, 52-week treatment period): In patients with moderate-to-severe asthma receiving SoC asthma therapy, to evaluate the long-term safety of QAW039 (150 mg once daily and...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Novartis Pharma AG, Basel
MAJ Il y a 5 ans
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
This study is designed to investigate the safety and tolerability of PTH134 in healthy subjects and to assess the exposure from PTH134.
Pays
Switzerland
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis
Study CFTY720D2301E1 is designed to assess the following properties of FTY720 in patients with relapsing MS: • To evaluate long-term safety and tolerability • To evaluate long-term efficacy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Bronchodilator effects and safety of glycopyrronium bromide (25 ug and 50 ug o.d.) in asthma
To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared to placebo in terms of trough FEV1 (mean of 23h 15 min and 23 h 45 min post -dose) following 1 week of treatment in the resp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/10 mg versus amlodipine 10 mg alone for 8 weeks in hypertensive patients who are not adequately controlled on amlodipine 10 mg monotherapy
To demonstrate the efficacy of the combination of valsartan/amlodipine 160/10 mg, in patients with essential hypertension not adequately controlled on amlodipine 10 mg monotherapy, by testing the hypo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Study of efficacy and safety of QVA149 compared to standard of care, a combination of fluticasone/salmeterol, in patients with moderate to severe COPD
To demonstrate the superiority of QVA149 27.5/12.5 μg twice a day as compared to fluticasone/salmeterol 250/50 μg twice a day in COPD patients with moderate to severe airflow limitation in terms of ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
An open label phase II study to find out if the drug PDR001 is safe and has beneficial effects in patient who have advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal, or thoracic origins and have progressed on prior treatment
To estimate the antitumor activity of PDR001 as a single agent in patients with non-functional NET
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
To evaluate the safety and tolerability of ribociclib with letrozole in men and pre/postmenopausal women with HR+, HER2- aBC who received no prior hormonal therapy for advanced disease
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Secukinumab safety and efficacy in JPsA and ERA
To demonstrate that the time to flare in Treatment Period 2 is longer with secukinumab for combined ERA and JPsA groups than with placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A safety and efficacy study to learn how well JM112 works in patients with moderate to severe inflammatory acne
To assess the efficacy of CJM112 versus placebo on facial inflammatory lesion counts in patients with moderate to severe inflammatory acne
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant